Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine.
作者信息
Lumish Melissa, Thackray Jennifer, Do Richard Kinh Gian, Caudle Kelly E, Amstutz Ursula, Schwab Matthias, Diasio Robert B, Jarnagin William R, Cercek Andrea
机构信息
Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
JCO Precis Oncol. 2023 Feb;7:e2200442. doi: 10.1200/PO.22.00442.
Abstract
摘要
相似文献
1
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine.使用肝动脉氟尿苷对二氢嘧啶脱氢酶缺乏症和以肝脏为主的转移性直肠癌患者进行精准管理。
JCO Precis Oncol. 2023 Feb;7:e2200442. doi: 10.1200/PO.22.00442.
2
Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver.围手术期辅助肝动脉注射丝裂霉素C和氟尿嘧啶联合手术切除肝脏转移性结直肠癌
Cancer. 1987 Mar 1;59(5):867-73. doi: 10.1002/1097-0142(19870301)59:5<867::aid-cncr2820590502>3.0.co;2-j.
3
Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine.接受氟尿苷肝动脉灌注的患者的胆汁性硬化
J Clin Oncol. 1985 Jan;3(1):98-102. doi: 10.1200/JCO.1985.3.1.98.
4
Preliminary results of a randomized study of intrahepatic infusion versus systemic infusion of 5-fluoro-2'-deoxyuridine for metastatic colorectal carcinoma.肝内输注与全身输注5-氟-2'-脱氧尿苷治疗转移性结直肠癌的随机研究初步结果
Recent Results Cancer Res. 1986;100:171-8. doi: 10.1007/978-3-642-82635-1_22.
5
Regional and systemic chemotherapy for colorectal metastases to the liver.用于治疗结直肠癌肝转移的区域化疗和全身化疗。
World J Surg. 1987 Aug;11(4):521-6. doi: 10.1007/BF01655818.
6
Regional infusion of fluoropyrimidines for hepatic metastases of colorectal cancer.氟尿嘧啶区域灌注治疗结直肠癌肝转移
Pharm Weekbl Sci. 1988 Apr 22;10(2):69-75. doi: 10.1007/BF01962681.
7
Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy?氟尿苷诱导的硬化性胆管炎：一种缺血性胆管病？
Hepatology. 1989 Feb;9(2):215-8. doi: 10.1002/hep.1840090209.
8
Pilot study of intra-arterial floxuridine, mitomycin and doxorubicin in combination with degradable starch microspheres to treat primary and metastatic tumors of the liver.动脉内注射氟尿苷、丝裂霉素和阿霉素联合可降解淀粉微球治疗原发性和转移性肝癌的初步研究。
Cancer Drug Deliv. 1985 Fall;2(4):305-11. doi: 10.1089/cdd.1985.2.305.
9
P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases.P53突变与结直肠癌肝转移患者对肝动脉氟尿苷的反应
J Cancer Res Clin Oncol. 2001 Nov;127(11):675-80. doi: 10.1007/s004320100248.
10
Implantable vascular access devices in the treatment of colorectal liver metastases.植入式血管通路装置在结直肠癌肝转移治疗中的应用
Br J Surg. 1986 Jun;73(6):419-21. doi: 10.1002/bjs.1800730602.
本文引用的文献
1
[Pharmacogenetic diagnostics to improve drug therapy in clinical practice].[用于改善临床实践中药物治疗的药物遗传学诊断]
Dtsch Med Wochenschr. 2021 Jan;146(1):e21. doi: 10.1055/a-1346-4382. Epub 2021 Jan 7.
2
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.短程放疗联合化疗后行全直肠系膜切除术（TME）与术前放化疗、TME 及辅助化疗在局部进展期直肠癌（RAPIDO）中的应用：一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7.
3
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.荷兰药物遗传学工作组（DPWG）关于 DPYD 和氟嘧啶类药物基因-药物相互作用的指南。
Eur J Hum Genet. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19.
4
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.基于 DPYD 基因型的氟嘧啶类药物个体化剂量在癌症患者中的应用：一项前瞻性安全性分析。
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
5
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.临床药物遗传学实施联盟（CPIC）关于二氢嘧啶脱氢酶基因型和氟嘧啶剂量的指南：2017 年更新。
Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.
6
Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.rs75017182对二氢嘧啶脱氢酶mRNA剪接和酶活性的定量贡献
Clin Pharmacol Ther. 2017 Oct;102(4):662-670. doi: 10.1002/cpt.685. Epub 2017 May 26.
7
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.DPYD 变异 c.1679T>G、c.1236G>A/HapB3 和 c.1601G>A 作为预测氟嘧啶类药物相关严重毒性的指标的临床意义：一项基于个体患者数据的系统评价和荟萃分析。
Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23.
8
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. upfront 基因分型 DPYD*2A 以实现氟尿嘧啶类药物个体化治疗：安全性和成本分析。
J Clin Oncol. 2016 Jan 20;34(3):227-34. doi: 10.1200/JCO.2015.63.1325. Epub 2015 Nov 16.
9
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.二氢嘧啶脱氢酶基因是预测氟尿嘧啶严重毒性的主要指标。
Pharmacogenomics. 2011 Sep;12(9):1321-36. doi: 10.2217/pgs.11.72.
10
PharmGKB summary: fluoropyrimidine pathways.药物基因组学知识库摘要：氟嘧啶代谢途径。
Pharmacogenet Genomics. 2011 Apr;21(4):237-42. doi: 10.1097/FPC.0b013e32833c6107.
Zotero 插件